



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Effects of Chemotherapy Dose Reductions in Overweight and Obese Patients with Acute Myeloid Leukemia – A Danish Nationwide Cohort Study

Kristensen, Daniel; Nielsen, Lars Børty; Jakobsen, Lasse Hjort; Kristensen, Tove-Christina Choe; El-Galaly, Tarec Christoffer; Roug, Anne Stidsholt; Severinsen, Marianne Tang

Published in:
HemaSphere

DOI (link to publication from Publisher):
[10.1097/01.HS9.0000845072.82360.17](https://doi.org/10.1097/01.HS9.0000845072.82360.17)

Creative Commons License
CC BY-NC-ND 4.0

Publication date:
2022

Document Version
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Kristensen, D., Nielsen, L. B., Jakobsen, L. H., Kristensen, T.-C. C., El-Galaly, T. C., Roug, A. S., & Severinsen, M. T. (2022). Effects of Chemotherapy Dose Reductions in Overweight and Obese Patients with Acute Myeloid Leukemia – A Danish Nationwide Cohort Study. *HemaSphere*, 6(Suppl. 3), 858-859. Article P546. <https://doi.org/10.1097/01.HS9.0000845072.82360.17>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

P546 EFFECTS OF CHEMOTHERAPY DOSE REDUCTIONS IN OVERWEIGHT AND OBESE PATIENTS WITH ACUTE MYELOID LEUKEMIA – A DANISH NATIONWIDE COHORT STUDY

Topic: 04. Acute myeloid leukemia - Clinical

Daniel Kristensen^{1, 2}, Lars Børty Nielsen^{2, 1}, Lasse Hjort Jakobsen^{1, 3}, Tove-Christina Choe Kristensen¹, Tarek Christoffer El-Galaly^{1, 2}, Anne Stidsholt Roug^{2, 1, 4}, Marianne Tang Severinsen^{1, 2}

¹ Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; ² Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; ³ Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark; ⁴ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

Background: The majority of chemotherapeutic agents are dosed according to a body weight derived variable. Studies in solid cancers have shown that overweight patients frequently receive dose reduction (DR) of chemotherapy, despite no evidence corroborates increased toxicity of full dosing. Rather, DR to $\leq 95\%$ of actual weight-based dose, has been shown to result in shortened overall survival (OS). Consequently, the American Society of Clinical Oncology does not recommend up-front dose reduction based on body mass index (BMI) or body surface area (BSA) in overweight patients. Current evidence regarding DR and outcome among overweight patients with acute myeloid leukemia (AML) receiving induction chemotherapy (IC) is limited.

Aims: The purpose of this study was to investigate the association between DR and outcome in overweight patients with AML.

Methods:

We utilized the Danish National Acute Leukemia Registry to conduct a retrospective cohort study. Overweight (BMI ≥ 25) AML patients aged 18-75 years and treated with IC between 2000-2012 were included. We defined DR as $\leq 95\%$ of actual BSA-based chemotherapy dose. Relative risks (RR) for DR, complete remission (CR) rates, and 30- and 90-day mortality were modeled, and OS and relapse-free-survival (RFS) were calculated and compared using the 5-year restricted mean survival time difference ($\Delta 5y$ -RMST).

Results:

The study population included 536 overweight AML-patients of whom 54 patients (10.1%) were categorized as DR (mean reduction 11.2%). Risk factors for DR in univariate analysis were increasing BMI (30-34.9: RR, 2.52 [95% CI, 1.32-4.71]; ≥ 35 : RR, 4.66 [95% CI, 2.37-8.91]), increasing BSA (2.0-2.2: RR 4.61 [95% CI, 1.96-12.6]; ≥ 2.2 : RR 15.21 [95% CI, 6.75-40.67]), therapy-related AML (RR 2.85 [95% CI, 1.12-7.24]) and favorable risk cytogenetics (RR 2.20 [95% CI, 1.02-4.33]). No significant differences were observed for rates of CR, 30- and 90-day mortality between patients receiving DR and non-DR IC. Dose reduction did not affect median RFS (DR, 14.5 [95% CI, 9.0 to 41.7] months; non-DR, 15.0 [12.3 to 19.3]) with an adjusted $\Delta 5y$ -RMST of 0.2 (-8.4 to 8.8) months nor median OS (DR, 17.0 [11.9-45.5] months; non-DR, 17.5 [14.8-20.5]) with an adjusted $\Delta 5y$ -RMST of 0.8 (-5.7 to 7.3) months (figure panel A+C). We constructed a case-matched cohort matched on age, sex, AML subtype and BMI (figure panel B+D) and performed a sensitivity analysis using $\leq 90\%$ cut-off to define DR which led to the same conclusions.


Image:

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.



Summary/Conclusion: This study demonstrates that ~10% of Danish overweight AML-patients treated with IC are dose reduced $\geq 5\%$ compared to full BSA-based doses. Risk factors were increasing BMI and BSA in addition

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

to therapy-related AML and favorable cytogenetic risk. Importantly, our results suggest that IC dose reduction does not adversely impact AML outcomes including 30- and 90-day mortality, rates of CR, RFS and OS. However, we encourage future prospective clinical studies to address this question with specific and uniform standards or protocol specifications for dose reduction or dose capping in overweight and obese patients with AML.

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.